Jobevne Injection
NDC 83257-009
Product Information
Jobevne (bevacizumab-nwgd) is a BLA-approved product labeled by Biocon Biologics Inc.. This medication is a man-made antibody (IgG1) used to treat various types of cancer. It is supplied as a injection for intravascular administration. This product entry covers the primary NDC 83257-009 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 83257-009?
What are the uses of this product?
What are Active Ingredients of this product?
- BEVACIZUMAB 25 mg/mL - An anti-VEGF humanized murine monoclonal antibody. It inhibits VEGF RECEPTORS and helps to prevent PATHOLOGIC ANGIOGENESIS.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- BEVACIZUMAB (UNII: 2S9ZZM9Q9V)
- BEVACIZUMAB (UNII: 2S9ZZM9Q9V) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- TREHALOSE DIHYDRATE (UNII: 7YIN7J07X4)
- POLYSORBATE 20 (UNII: 7T1F30V5YH)
- SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F)
- SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE (UNII: 5QWK665956)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2712048 - bevacizumab-nwgd 100 MG in 4 ML Injection
- RxCUI: 2712048 - 4 ML bevacizumab-nwgd 25 MG/ML Injection
- RxCUI: 2712048 - bevacizumab-nwgd 100 MG per 4 ML Injection
- RxCUI: 2712055 - Jobevne 100 MG in 4 ML Injection
- RxCUI: 2712055 - 4 ML bevacizumab-nwgd 25 MG/ML Injection [Jobevne]
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.